Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Genome-wide discovery of somatic coding and non-coding mutations in pediatric endemic and sporadic Burkitt lymphoma.

Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, Allen H, Ayers LW, Bethony JM, Bhatia K, Bowen J, Casper C, Choi JK, Culibrk L, Davidsen TM, Dyer MA, Gastier-Foster JM, Gesuwan P, Greiner TC, Gross TG, Hanf B, Harris NL, He Y, Irvin JD, Jaffe ES, Jones SJM, Kerchan P, Knoetze N, Leal FE, Lichtenberg TM, Ma Y, Martin JP, Martin MR, Mbulaiteye SM, Mullighan CG, Mungall AJ, Namirembe C, Novik K, Noy A, Ogwang MD, Omoding A, Orem J, Reynolds SJ, Rushton CK, Sandlund JT, Schmitz R, Taylor C, Wilson WH, Wright GW, Zhao EY, Marra MA, Morin RD, Staudt LM.

Blood. 2019 Jan 7. pii: blood-2018-09-871418. doi: 10.1182/blood-2018-09-871418. [Epub ahead of print]

PMID:
30617194
2.

Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma.

Qualls D, Abramson JS.

Haematologica. 2019 Jan;104(1):25-34. doi: 10.3324/haematol.2018.195834. Epub 2018 Dec 20. Review.

3.

Design and clinical validation of a point-of-care device for the diagnosis of lymphoma via contrast-enhanced microholography and machine learning.

Im H, Pathania D, McFarland PJ, Sohani AR, Degani I, Allen M, Coble B, Kilcoyne A, Hong S, Rohrer L, Abramson JS, Dryden-Peterson S, Fexon L, Pivovarov M, Chabner B, Lee H, Castro CM, Weissleder R.

Nat Biomed Eng. 2018 Sep;2(9):666-674. doi: 10.1038/s41551-018-0265-3. Epub 2018 Jul 23.

PMID:
30555750
4.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH.

Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.

PMID:
30501868
5.

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC.

N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.

PMID:
30501481
6.

Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana.

Milligan MG, Bigger E, Abramson JS, Sohani AR, Zola M, Kayembe MKA, Medhin H, Suneja G, Lockman S, Chabner BA, Dryden-Peterson SL.

J Glob Oncol. 2018 Sep;(4):1-11. doi: 10.1200/JGO.17.00084.

7.

EEG findings in CAR T-cell therapy-related encephalopathy.

Herlopian A, Dietrich J, Abramson JS, Cole AJ, Westover MB.

Neurology. 2018 Jul 31;91(5):227-229. doi: 10.1212/WNL.0000000000005910. Epub 2018 Jun 29. No abstract available.

PMID:
29959264
8.

Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.

Barnes JA, Redd R, Fisher DC, Hochberg EP, Takvorian T, Neuberg D, Jacobsen E, Abramson JS.

Hematol Oncol. 2018 Oct;36(4):633-637. doi: 10.1002/hon.2515. Epub 2018 Jun 28.

PMID:
29956350
9.

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM.

Blood Adv. 2017 Dec 11;1(26):2600-2609. doi: 10.1182/bloodadvances.2017009472. eCollection 2017 Dec 12.

10.

More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.

Abramson JS, Chen YB.

N Engl J Med. 2017 Nov 23;377(21):2102. doi: 10.1056/NEJMc1712460. No abstract available.

PMID:
29166240
11.

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2017 Nov;15(11):1414-1427. doi: 10.6004/jnccn.2017.0165.

PMID:
29118233
12.

Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines.

Kim L, Rha B, Abramson JS, Anderson LJ, Byington CL, Chen GL, DeVincenzo J, Edwards KM, Englund JA, Falsey AR, Griffin MR, Karron RA, Martin KG, Meissner HC, Munoz FM, Pavia AT, Piedra PA, Schaffner W, Simões EAF, Singleton R, Talbot HK, Walsh EE, Zucker JR, Gerber SI.

Clin Infect Dis. 2017 Sep 15;65(6):1020-1025. doi: 10.1093/cid/cix432.

13.

Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.

Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen YB, Palmer E, Albertson T, Ferry JA, Arrillaga-Romany IC.

N Engl J Med. 2017 Aug 24;377(8):783-784. doi: 10.1056/NEJMc1704610. No abstract available.

PMID:
28834486
14.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE.

Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Review.

15.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2017 Mar;15(3):293-311.

PMID:
28275031
16.

Case 5-2017. A 19-Year-Old Man with Hematuria and a Retroperitoneal Mass.

Blute ML Sr, Abramson JS, Cronin KC, Nardi V.

N Engl J Med. 2017 Feb 16;376(7):684-692. doi: 10.1056/NEJMcpc1610100. No abstract available.

PMID:
28199810
17.

Recurrent mutations and targeted therapy in FL.

Abramson JS.

Blood. 2017 Jan 26;129(4):402-403. doi: 10.1182/blood-2016-12-753145. No abstract available.

18.

The Spectrum of Double Hit Lymphomas.

Abramson JS.

Hematol Oncol Clin North Am. 2016 Dec;30(6):1239-1249. doi: 10.1016/j.hoc.2016.07.005. Review.

PMID:
27888878
19.

Imaging for Oncologic Response Assessment in Lymphoma.

Kulkarni NM, Pinho DF, Narayanan S, Kambadakone AR, Abramson JS, Sahani DV.

AJR Am J Roentgenol. 2017 Jan;208(1):18-31. doi: 10.2214/AJR.16.16180. Epub 2016 Oct 27. Review.

PMID:
27786547
20.

Bone marrow biopsies for staging of diffuse large B-cell lymphoma: are we looking too closely?

Abramson JS.

Leuk Lymphoma. 2017 Jan;58(1):4-5. Epub 2016 Oct 25. No abstract available.

PMID:
27778520
21.

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P.

J Natl Compr Canc Netw. 2016 Sep;14(9):1067-79.

PMID:
27587620
22.

Holographic Assessment of Lymphoma Tissue (HALT) for Global Oncology Field Applications.

Pathania D, Im H, Kilcoyne A, Sohani AR, Fexon L, Pivovarov M, Abramson JS, Randall TC, Chabner BA, Weissleder R, Lee H, Castro CM.

Theranostics. 2016 Jun 18;6(10):1603-10. doi: 10.7150/thno.15534. eCollection 2016.

23.

The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.

Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR.

Am J Hematol. 2016 Oct;91(10):E436-41. doi: 10.1002/ajh.24485. Epub 2016 Aug 4.

24.

Strengthening maternal immunisation to improve the health of mothers and infants.

Abramson JS, Mason E.

Lancet. 2016 Nov 19;388(10059):2562-2564. doi: 10.1016/S0140-6736(16)30882-0. Epub 2016 Jun 29. No abstract available.

PMID:
27372397
25.

Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients.

Atkinson W, Catana C, Abramson JS, Arabasz G, McDermott S, Catalano O, Muse V, Blake MA, Barnes J, Shelly M, Hochberg E, Rosen BR, Guimaraes AR.

Abdom Radiol (NY). 2016 Jul;41(7):1338-48. doi: 10.1007/s00261-016-0638-6.

PMID:
27315095
26.

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR.

Blood. 2016 Jul 14;128(2):195-203. doi: 10.1182/blood-2016-03-707133. Epub 2016 May 31.

27.

Chemotherapy-sparing treatment strategies for follicular lymphoma: current options and future directions.

Ng SY, Abramson JS.

Curr Opin Hematol. 2016 Jul;23(4):371-6. doi: 10.1097/MOH.0000000000000263. Review.

PMID:
27213499
28.

Mind the gap: jumping from vaccine licensure to routine use.

O'Brien KL, Binka F, Marsh K, Abramson JS.

Lancet. 2016 May 7;387(10031):1887-9. doi: 10.1016/S0140-6736(16)30394-4. No abstract available.

PMID:
27203633
29.

Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation.

von Tresckow B, Morschhauser F, Szer J, Eichenauer DA, Abramson JS, Sureda A, Engert A.

Leuk Lymphoma. 2017 Jan;58(1):222-225. Epub 2016 May 17. No abstract available.

PMID:
27184350
30.

Small-cell predominant extranodal NK/T cell lymphoma, nasal type: clinicopathological analysis of a series of cases diagnosed in a Western population.

McKelvie PA, Climent F, Krings G, Hasserjian RP, Abramson JS, Pilch BZ, Harris NL, Ferry JA, Zukerberg LR, Sohani AR.

Histopathology. 2016 Oct;69(4):667-79. doi: 10.1111/his.12990. Epub 2016 Jun 21.

PMID:
27144366
31.

A lifetime journey through clinical care, research and public health.

Abramson JS.

Hum Vaccin Immunother. 2016 Nov;12(11):2723-2725. Epub 2016 Apr 29. No abstract available.

32.

Diffuse Large B-Cell Lymphoma Version 1.2016.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H.

J Natl Compr Canc Netw. 2016 Feb;14(2):196-231.

PMID:
26850490
33.

De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.

Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, Park SI, Matthews S, Abramson JS, Iris Lim H, Martin P, Cohen JB, Evens A, Al-Mansour Z, Singavi A, Fenske TS, Blum KA.

Am J Hematol. 2016 Jun;91(4):395-9. doi: 10.1002/ajh.24299.

34.

MYC/BCL2 double-expression vs. cell-of-origin classification in diffuse large B-cell lymphoma: do we need to know both?

Sohani AR, Abramson JS.

Leuk Lymphoma. 2016;57(3):509-11. doi: 10.3109/10428194.2015.1115046. Epub 2015 Dec 23. No abstract available.

PMID:
26693593
35.

Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.

Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M, Shah N, Fenske TS, Jaso J, Medeiros LJ, Yang DT, Nabhan C.

Cancer. 2016 Feb 15;122(4):559-64. doi: 10.1002/cncr.29781. Epub 2015 Nov 13.

36.

Evaluation of a Mentoring Program for New Pediatric Department Chairs.

Wilmott RW, Abramson JS, Davies HD, Felice ME, Stanton B, Jacobs RF.

J Pediatr. 2015 Oct;167(4):787-8. doi: 10.1016/j.jpeds.2015.06.069. No abstract available.

PMID:
26409762
37.

Transformative Clinical Trials in Non-Hodgkin and Hodgkin Lymphomas.

Abramson JS.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S141-6. doi: 10.1016/j.clml.2015.02.006. Review.

PMID:
26297267
38.

Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy.

Wang L, Tan TC, Halpern EF, Neilan TG, Francis SA, Picard MH, Fei H, Hochberg EP, Abramson JS, Weyman AE, Kuter I, Scherrer-Crosbie M.

Am J Cardiol. 2015 Aug 1;116(3):442-6. doi: 10.1016/j.amjcard.2015.04.064. Epub 2015 May 14.

PMID:
26071994
39.

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA.

Am J Hematol. 2015 Sep;90(9):778-83. doi: 10.1002/ajh.24082.

40.

Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information.

Nardi V, Pulluqi O, Abramson JS, Dal Cin P, Hasserjian RP.

Am J Hematol. 2015 Jun;90(6):529-33. doi: 10.1002/ajh.24008. Epub 2015 May 3.

41.

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H; National comprehension cancer network.

J Natl Compr Canc Netw. 2015 Mar;13(3):326-62.

42.

Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma.

Abramson JS, Chung RT.

JAMA. 2014 Dec 17;312(23):2505-7. doi: 10.1001/jama.2014.16095. No abstract available.

PMID:
25514300
43.

Diagnosis and management of Castleman disease.

Soumerai JD, Sohani AR, Abramson JS.

Cancer Control. 2014 Oct;21(4):266-78. Review.

PMID:
25310208
44.

Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.

Castillo JJ, Bower M, Brühlmann J, Novak U, Furrer H, Tanaka PY, Besson C, Montoto S, Cwynarski K, Abramson JS, Dalia S, Bibas M, Connors JM, Furman M, Nguyen ML, Cooley TP, Beltran BE, Collins JA, Vose JM, Xicoy B, Ribera JM; HIV-Associated Hodgkin Lymphoma in the cART Era Study Group.

Cancer. 2015 Feb 1;121(3):423-31. doi: 10.1002/cncr.29066. Epub 2014 Sep 23.

45.

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.

Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM.

Ann Oncol. 2014 Nov;25(11):2211-7. doi: 10.1093/annonc/mdu443. Epub 2014 Sep 5.

46.

Non-Hodgkin's lymphomas, version 4.2014.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Sep;12(9):1282-303.

47.

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS.

Blood. 2014 Oct 9;124(15):2354-61. doi: 10.1182/blood-2014-05-578963. Epub 2014 Aug 26.

48.

Addressing the growing cancer burden in the wake of the AIDS epidemic in Botswana: The BOTSOGO collaborative partnership.

Efstathiou JA, Bvochora-Nsingo M, Gierga DP, Alphonse Kayembe MK, Mmalane M, Russell AH, Paly JJ, Brown C, Musimar Z, Abramson JS, Bruce KA, Karumekayi T, Clayman R, Hodgeman R, Kasese J, Makufa R, Bigger E, Suneja G, Busse PM, Randall TC, Chabner BA, Dryden-Peterson S.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):468-75. doi: 10.1016/j.ijrobp.2014.03.033.

49.

Non-Hodgkin's lymphomas, version 2.2014.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H.

J Natl Compr Canc Netw. 2014 Jun;12(6):916-46.

PMID:
24925202
50.

Extranodal Marginal Zone Lymphoma Presenting As Miliary Lung Disease.

Abramson JS, Ferry JA, Muse VV, Lanuti M.

J Clin Oncol. 2016 Feb 1;34(4):e27-30. doi: 10.1200/JCO.2013.50.6501. Epub 2014 Jun 9. No abstract available.

PMID:
24912892

Supplemental Content

Loading ...
Support Center